Keros Therapeutics, Inc. has announced the effectiveness of a global development and commercialization license agreement with Takeda to advance elritercept, which became effective on January 16, 2025. This agreement follows the expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. As part of this agreement, Takeda will make an upfront payment of $200.0 million to Keros.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue.
Keros has discovered and is developing protein therapeutics with the potential to provide meaningful and potentially disease-modifying benefits to patients. Notably, cibotercept is being developed for the treatment of pulmonary arterial hypertension and cardiovascular disorders, while ker-065 is being developed for the treatment of neuromuscular diseases. Elritercept, the focus of the recent agreement with Takeda, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis.
The agreement with Takeda represents a significant milestone for Keros Therapeutics, Inc. as it seeks to advance its therapeutic pipeline and potentially bring meaningful treatments to patients with a range of disorders associated with dysfunctional signaling of the TGF-ß family of proteins. Following these announcements, the company's shares moved 5.2%, and are now trading at a price of $11.42. Check out the company's full 8-K submission here.
